CN115925780B - 含有Fc的蛋白的纯化方法 - Google Patents

含有Fc的蛋白的纯化方法

Info

Publication number
CN115925780B
CN115925780B CN202210979746.6A CN202210979746A CN115925780B CN 115925780 B CN115925780 B CN 115925780B CN 202210979746 A CN202210979746 A CN 202210979746A CN 115925780 B CN115925780 B CN 115925780B
Authority
CN
China
Prior art keywords
protein
antibody
antibodies
region
mobile phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210979746.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN115925780A (zh
Inventor
J.K.卡乌亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CN115925780A publication Critical patent/CN115925780A/zh
Application granted granted Critical
Publication of CN115925780B publication Critical patent/CN115925780B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/34—Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B01D15/426—Specific type of solvent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Storage Device Security (AREA)
CN202210979746.6A 2016-07-22 2017-07-21 含有Fc的蛋白的纯化方法 Active CN115925780B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662365943P 2016-07-22 2016-07-22
US62/365943 2016-07-22
CN201780045463.1A CN109563125B (zh) 2016-07-22 2017-07-21 含有Fc的蛋白的纯化方法
PCT/US2017/043384 WO2018018011A2 (en) 2016-07-22 2017-07-21 Methods of purifying fc-containing proteins

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780045463.1A Division CN109563125B (zh) 2016-07-22 2017-07-21 含有Fc的蛋白的纯化方法

Publications (2)

Publication Number Publication Date
CN115925780A CN115925780A (zh) 2023-04-07
CN115925780B true CN115925780B (zh) 2025-11-04

Family

ID=59656168

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210979746.6A Active CN115925780B (zh) 2016-07-22 2017-07-21 含有Fc的蛋白的纯化方法
CN201780045463.1A Active CN109563125B (zh) 2016-07-22 2017-07-21 含有Fc的蛋白的纯化方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780045463.1A Active CN109563125B (zh) 2016-07-22 2017-07-21 含有Fc的蛋白的纯化方法

Country Status (12)

Country Link
US (1) US11312745B2 (https=)
EP (1) EP3487867B1 (https=)
JP (2) JP7092744B2 (https=)
KR (2) KR102579850B1 (https=)
CN (2) CN115925780B (https=)
AU (2) AU2017298984B2 (https=)
CA (2) CA3218290A1 (https=)
IL (2) IL285146B (https=)
MA (1) MA45721A (https=)
MX (2) MX2019000903A (https=)
SG (1) SG11201900573UA (https=)
WO (1) WO2018018011A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202102713TA (en) * 2018-09-21 2021-04-29 Teneobio Inc Methods for purifying heterodimeric, multispecific antibodies
JP7644706B2 (ja) * 2018-10-11 2025-03-12 アムジエン・インコーポレーテツド 二重特異性抗体コンストラクトの下流プロセシング
AU2020208360B2 (en) * 2019-01-16 2025-05-08 Regeneron Pharmaceuticals, Inc. Method and system of identifying and quantifying antibody fragmentation
KR102286892B1 (ko) * 2019-07-08 2021-08-06 삼천당제약주식회사 안과용 단백질 제제의 정제방법
CN110724204B (zh) * 2019-11-18 2021-10-22 广东菲鹏制药股份有限公司 Fc融合蛋白的纯化方法
CN112881675A (zh) * 2019-11-29 2021-06-01 广东菲鹏生物有限公司 IgM抗体检测稀释液
JP2023521384A (ja) 2020-04-09 2023-05-24 シートムエックス セラピューティクス，インコーポレイテッド 活性化可能抗体を含む組成物
WO2022061035A1 (en) * 2020-09-16 2022-03-24 Waters Technologies Corporation Improved size exclusion chromatography utilizing low concentration amino acids in size exclusion chromatography mobile phase
CN118414350A (zh) * 2021-10-19 2024-07-30 阿特根公司 纯化具有igg fc结构域的融合蛋白的方法
CN113980092B (zh) * 2021-12-09 2024-05-14 上海药明生物技术有限公司 一种蛋白质亲和纯化方法
CN116165290B (zh) * 2021-12-17 2025-06-27 复旦大学 一种抗体药物研发流程中工程细胞株的筛选方法
CN116271982B (zh) * 2022-11-30 2024-01-09 杭州广科安德生物科技有限公司 一种血液高丰度蛋白免疫亲和柱的再生方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101213211A (zh) * 2005-06-17 2008-07-02 惠氏公司 纯化含Fc区蛋白的方法
CN102171237A (zh) * 2008-08-14 2011-08-31 默沙东公司 使用蛋白a亲和色谱法纯化抗体的方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
CA2325022A1 (en) * 1998-04-16 1999-10-21 Genentech, Inc. Secretion of glycosylated proteins using a tissue plasminogen activator pro-sequence
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
AU2005299716B2 (en) * 2004-10-22 2012-09-06 Amgen Inc. Methods for refolding of recombinant antibodies
WO2007081906A2 (en) * 2006-01-06 2007-07-19 Amgen Inc. Purification by column-chromatography using eluants containing organic solvents
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
WO2008036600A2 (en) * 2006-09-18 2008-03-27 Genentech, Inc. Methods of protein production
JP5522723B2 (ja) 2007-05-21 2014-06-18 ノマディックバイオサイエンス株式会社 新規ポリペプチド，アフィニティークロマトグラフィー用材，及びイムノグロブリンの分離及び／又は精製方法
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
EP3366692A1 (en) * 2009-06-22 2018-08-29 Amgen, Inc Refolding proteins using a chemically controlled redox state
AU2010266093B2 (en) * 2009-06-25 2013-06-27 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
EP2478013B1 (en) 2009-09-16 2018-10-24 F.Hoffmann-La Roche Ag Coiled coil and/or tether containing protein complexes and uses thereof
CN102382190B (zh) * 2010-09-01 2014-04-09 山东新时代药业有限公司 分离和去除TNFR-Fc融合蛋白中寡聚体的方法
US20130317172A1 (en) 2010-12-24 2013-11-28 Nomadic Bioscience Co., Ltd. Method for immobilizing temperature responsive protein a
DK2729482T3 (en) * 2011-07-08 2018-05-07 Merck Sharp & Dohme PROCEDURE FOR CLEANING FC-FUSION PROTEIN
EP2831096B1 (en) 2012-03-28 2020-04-29 GE Healthcare BioProcess R&D AB Affinity chromatography matrix
JP6253584B2 (ja) 2012-08-27 2017-12-27 旭化成メディカル株式会社 温度応答性クロマトグラフィーによる抗体の精製方法
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
JP2016538275A (ja) * 2013-11-04 2016-12-08 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101213211A (zh) * 2005-06-17 2008-07-02 惠氏公司 纯化含Fc区蛋白的方法
CN102171237A (zh) * 2008-08-14 2011-08-31 默沙东公司 使用蛋白a亲和色谱法纯化抗体的方法

Also Published As

Publication number Publication date
EP3487867A2 (en) 2019-05-29
CN115925780A (zh) 2023-04-07
KR20220120716A (ko) 2022-08-30
US20190127418A1 (en) 2019-05-02
CA3218290A1 (en) 2018-01-25
IL264375A (en) 2019-02-28
IL285146B (en) 2022-09-01
CA3031469C (en) 2025-11-18
IL264375B (en) 2021-09-30
US11312745B2 (en) 2022-04-26
SG11201900573UA (en) 2019-02-27
AU2017298984A1 (en) 2019-02-07
AU2023222915A1 (en) 2023-09-21
MX2019000903A (es) 2019-05-15
CN109563125A (zh) 2019-04-02
MX2023006291A (es) 2023-06-13
JP7411020B2 (ja) 2024-01-10
EP3487867B1 (en) 2026-04-01
AU2017298984B2 (en) 2023-08-31
JP2019528255A (ja) 2019-10-10
KR102435801B1 (ko) 2022-08-25
AU2023222915B2 (en) 2026-01-22
WO2018018011A3 (en) 2018-03-01
JP2022120138A (ja) 2022-08-17
KR20190037247A (ko) 2019-04-05
KR102579850B1 (ko) 2023-09-18
WO2018018011A2 (en) 2018-01-25
JP7092744B2 (ja) 2022-06-28
CA3031469A1 (en) 2018-01-25
IL285146A (en) 2021-08-31
MA45721A (fr) 2019-05-29
CN109563125B (zh) 2022-08-09

Similar Documents

Publication Publication Date Title
CN115925780B (zh) 含有Fc的蛋白的纯化方法
US9334319B2 (en) Low acidic species compositions
US20160115193A1 (en) Novel purification of antibodies using hydrophobic interaction chromatography
US20130336957A1 (en) Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
AU2018326458B2 (en) Method for purifying proteins
HU217850B (hu) Eljárás antitest tisztítására
WO2012125735A1 (en) An integrated approach to the isolation and purification of antibodies
EP3676280B1 (en) Method for purifying anti-il-6 receptor antibodies
HK40109504A (zh) 用羟基磷灰石层析分离双特异性抗体和双特异性抗体生产副产物
HK40034198B (en) Method for purifying anti-il-6 receptor antibodies
HK40034198A (en) Method for purifying anti-il-6 receptor antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant